Search

Displaying results 2601 - 2610 of 10000 in total
  1. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … Miglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia.

  2. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    Polycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … Polycarbophil calcium is a synthetic polymer manufactured from the cross-linking of polyacrylic acid with divinyl glycol and a calcium counter-ion.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Interferon alfacon-1

    go.drugbank.com/drugs/DB00069
    ApprovedWithdrawn

    Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. … This protein has a molecular weight of 19,434 daltons.

  4. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.

    Categories: Heterocyclic Compounds with 4 or More Rings, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: CABERGOLIN-1A PHARMA1MG, CABERGOLIN-1A PHARMA2MG
  5. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274158] As part of the second-generation of ROS1 inhibitors, taletrectinib is significantly more potent against ROS1 resistance mutations - for example, the IC50 for taletrectinib against ROS1 exhibiting … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable

  6. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    It is being developed clinically as a once-daily oral therapy for the treatment of cancer. … The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.

  7. Drug

    Neuropeptide Y

    go.drugbank.com/drugs/DB11788
    ApprovedInvestigationalWithdrawn

    Neuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.

  8. Drug

    Sulesomab

    go.drugbank.com/drugs/DB13976
    Approved

    Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.

  9. Drug

    Granisetron

    go.drugbank.com/drugs/DB00889
    ApprovedInvestigational

    A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

    Products: Granodex 1mg/ml Solution for Injection or Infusion, Granisetron Kabi concentrate for solution for infusion 1mg/ml
  10. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.

    Categories: Antihypertensive Agents Indicated for Hypertension